news
Lynparza has been approved for BRCA-mutated advanced ovarian cancer
BRCA-mutated advanced ovarian cancer treatment has been approved by the European Commission.
List view / Grid view
Ovarian Cancer
Filter the results
news
Pivotal phase III trial launched in recurrent ovarian cancer
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer...
news
Losartan could improve ovarian cancer treatment
Researchers have found that losartan could be beneficial for those undergoing cancer treatment as it may enhance its effectiveness...
news
Ovarian cancer risks may be lowered with aspirin
A Harvard Chan School of Public Health study showed aspirin specifically in low doses could lower the risk of ovarian cancer...
news
Scientists identify cause of resistance to breast and ovarian cancer drug
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors...
news
Hemp shows potential for treating ovarian cancer
Researchers demonstrate hemp's ability to slow cancer growth and uncover mechanism for its cancer-fighting ability...
news
Ponatinib is found to be effective against SCCOHT
Ponatinib is effective against SCCOHT, a type of ovarian cancer that mostly strikes young women and girls as young as 14 months...
news
FDA approves lynparza for breast cancer with BRCA gene mutation
The FDA has expanded the approved use of Lynparza to include the treatment of patients with metastatic breast cancer who have a BRCA gene mutation...
news
Merrimack initiates Phase 1 study of MM-310 in solid tumours
29 March 2017 | By Niamh Marriott, Junior Editor
Merrimack Pharmaceuticals have enrolled its first patient in a Phase 1 study of MM-310 in solid tumours.
news
Lynparza Phase III data demonstrates progression-free survival in ovarian cancer
17 March 2017 | By Niamh Marriott, Junior Editor
AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator assessed PFS (HR 0.30; 95%…
news
Phase III trial to evaluate avelumab as first-line treatment in ovarian cancer
6 July 2016 | By Victoria White, Digital Content Producer
Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer...
news
Aprea announces efficacy and safety data for APR-246 in ovarian cancer
7 June 2016 | By Victoria White, Digital Content Producer
Aprea presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial of APR-246 at the ASCO annual meeting...
news
NICE says ‘yes’ to two ovarian cancer drugs, rejects three
27 April 2016 | By Victoria White, Digital Content Producer
The guidance recommends paclitaxel and PLDH for treating ovarian cancer that has returned after previous chemotherapy treatment...
news
TPIV 200 and durvalumab to be evaluated in a Phase II ovarian cancer study
22 April 2016 | By Victoria White, Digital Content Producer
TapImmune plans to initiate a Phase II trial of TPIV 200 in combination with AstraZeneca’s durvalumab in patients with platinum-resistant ovarian cancer...
news
ImmunoGen and Merck collaborate for ovarian cancer trial
5 February 2016 | By Victoria White
The companies are to are to assess ImmunoGen’s mirvetuximab soravtansine in combination with Merck’s Keytruda (pembrolizumab) in FRα-positive ovarian cancer...